Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Gains from Sales and Divestitures (2018 - 2025)

Nephros has reported Gains from Sales and Divestitures over the past 8 years, most recently at $70708.0 for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $70708.0 for Q4 2025, up 67.69% from a year ago — trailing twelve months through Dec 2025 was $70708.0 (up 67.69% YoY), and the annual figure for FY2025 was $70708.0, up 67.69%.
  • Gains from Sales and Divestitures for Q4 2025 was $70708.0 at Nephros, down from $160843.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for NEPH hit a ceiling of $187503.0 in Q4 2023 and a floor of $23781.0 in Q4 2021.
  • Median Gains from Sales and Divestitures over the past 5 years was $64834.5 (2025), compared with a mean of $91851.1.
  • Biggest five-year swings in Gains from Sales and Divestitures: crashed 99.96% in 2021 and later soared 319.17% in 2023.
  • Nephros' Gains from Sales and Divestitures stood at $23781.0 in 2021, then surged by 88.1% to $44732.0 in 2022, then soared by 319.17% to $187503.0 in 2023, then plummeted by 77.51% to $42167.0 in 2024, then skyrocketed by 67.69% to $70708.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $70708.0 (Q4 2025), $160843.0 (Q3 2025), and $146114.0 (Q2 2025) per Business Quant data.